Q-omics provides the consensus-scored PDZD8 profile across patient tissues and cancer cell-line models. PDZD8 expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, PDZD8 is differentially expressed in 10, with the highest sampling consensus in KIRP. Additionally, PDZD8 RNA expression shows 20,874 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight ACC, KIRP, and THYM as cancer lineages where PDZD8 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PDZD8 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PDZD8 survival associations across molecular data types. PDZD8 RNA expression shows survival associations in the most cancer types (26), followed by mutation status (10) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PDZD8 RNA expression–survival associations across cancer types. High PDZD8 expression shows unfavorable associations in ACC and BLCA, but favorable associations in SCLC, KIRC, LGG and UCS. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for PDZD8 RNA expression.
This table summarizes PDZD8 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10, while mass-spec protein shows differences in 5. The strongest signals are observed in KIRP for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for PDZD8. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PDZD8 shows lower tumor expression in THCA and higher tumor expression in KIRP, STAD, COAD, UCEC and ESCA. The KIRP box plot shows higher PDZD8 RNA expression in tumor versus normal tissue (log2 FC = +1.205, t-test p = .003).
This table shows molecular features associated with PDZD8 in patient tissues and cancer cell lines. In patient samples, PDZD8 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, PDZD8 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BREAST, while CRISPR and shRNA rows add functional-dependency signals in OESOPHAGUS and BLOOD_Leukemia.
